Skip to main content
Equibles

Vanguard Global Advisers, LLC

Position in DSGN — Design Therapeutics, Inc.

CIK 1811242 MALVERN, PA
Back to DSGN Full portfolio

Position in DSGN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$514,176
+$388,210 QoQ
Shares Held
35,534
+200.1% QoQ
Ownership
0.057%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#61
of 136 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in DSGN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Vanguard Global Advisers, LLC holds $820,531,237 across 371 Biotechnology names. DSGN ranks #118 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 547,463 $271,941,295
2 REGN
Regeneron Pharmaceuticals, Inc.
 226,724 $141,371,482
3 MRNA
Moderna, Inc.
 737,973 $51,680,249
4 INCY
Incyte Corp
 380,037 $43,080,994
5 TECH
BIO-TECHNE Corp
 324,090 $22,896,958
6 ALNY
Alnylam Pharmaceuticals, Inc.
 64,254 $19,342,381
7 RVMD
Revolution Medicines, Inc.
 82,088 $15,373,440
8 RPRX
Royalty Pharma plc
 230,477 $12,922,845

All Filings in DSGN

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $514,176 35,534
2026-03-31 $125,966 11,839